| dc.contributor |
Médecins Sans Frontières, Phnom Penh, Cambodia. b.janssens@bigfoot.com |
|
| dc.creator |
Janssens, B |
|
| dc.creator |
Van Herp, M |
|
| dc.creator |
Goubert, L |
|
| dc.creator |
Chan, S |
|
| dc.creator |
Uong, S |
|
| dc.creator |
Nong, S |
|
| dc.creator |
Socheat, D |
|
| dc.creator |
Brockman, A |
|
| dc.creator |
Ashley, E A |
|
| dc.creator |
Van Damme, W |
|
| dc.date |
2007-02 |
|
| dc.date.accessioned |
2017-01-31T07:09:37Z |
|
| dc.date.available |
2017-01-31T07:09:37Z |
|
| dc.identifier |
A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. 2007, 12 (2):251-9 Trop. Med. Int. Health |
|
| dc.identifier |
1360-2276 |
|
| dc.identifier |
17300633 |
|
| dc.identifier |
10.1111/j.1365-3156.2006.01786.x |
|
| dc.identifier |
http://hdl.handle.net/10144/17743 |
|
| dc.identifier |
http://fieldresearch.msf.org/msf/handle/10144/17743 |
|
| dc.identifier |
Tropical Medicine & International Health |
|
| dc.identifier.uri |
http://dspace.mediu.edu.my:8181/xmlui/handle/10144/17743 |
|
| dc.description |
OBJECTIVES: To compare the efficacy and tolerability of dihydroartemisinin-piperaquine (DHA-PQP) with that of a 3-day regimen of mefloquine and artesunate (MAS3) for the treatment of uncomplicated falciparum malaria in Cambodia. METHOD: Randomized open-label non-inferiority study over 64 days. RESULTS: Four hundred and sixty-four patients were included in the study. The polymerase chain reaction genotyping-adjusted cure rates on day 63 were 97.5% (95% confidence interval, CI, 93.8-99.3) for DHA-PQP and 97.5% (95% CI, 93.8-99.3) for MAS3, P = 1. There were no serious adverse events, but significantly more episodes of vomiting (P = 0.03), dizziness (P = 0.002), palpitations (P = 0.04), and sleep disorders (P = 0.03) reported in the MAS3 treatment group, consistent with the side-effect profile of mefloquine. CONCLUSIONS: DHA-PQP was as efficacious as MAS3, but much better tolerated, making it more appropriate for use in a routine programme setting. This highly efficacious, safe and more affordable fixed-dose combination could become the treatment of choice for Plasmodium falciparum malaria in Cambodia. |
|
| dc.language |
en |
|
| dc.publisher |
Wiley-Blackwell |
|
| dc.relation |
http://www.blackwell-synergy.com/loi/tmi |
|
| dc.rights |
Archived on this site with the kind permission of Wiley-Blackwell |
|
| dc.title |
A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. |
|